Drug Trial Radar · NCT06511570
A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Oct 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Jun 25, 2024
Primary completion
Sep 17, 2024
Study completion Sep 17, 2024
Sponsor
- Lead sponsor
- Acumen PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jul 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants
Conditions
- Alzheimer Disease
Interventions
sabirnetug (ACU193)Drug
sabirnetug by intravenous infusion
Sabirnetug + rHuPH20Combination product
sabirnetug + rHuPH20 by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Estimate blood levels of sabirnetug (ACU193)Time frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50
- Estimate time to reach maximum blood levels of sabirnetug (ACU193)Time frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50
- Estimate blood levels of sabirnetug (ACU193), terminal rateTime frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50
- Estimate time to reach half-life blood levels of sabirnetug (ACU193), half-lifeTime frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50
- Estimate blood levels of sabirnetug (ACU193), concentration-timeTime frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50
- Estimate blood levels of sabirnetug (ACU193), last concentration-timeTime frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50
- Estimate blood levels of sabirnetug (ACU193), infinity concentration-timeTime frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50
- Estimate blood levels of sabirnetug (ACU193), extrapolationTime frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50
- Estimate blood levels of sabirnetug (ACU193), ClastTime frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50
- Estimate time to reach last blood levels of sabirnetug (ACU193)Time frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Worldwide Clinical Trials
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.